Darolutamide Approved for Patients with mHSPC - Charles Ryan
Charles Ryan
Drs Charles Ryan and Alicia Morgans discuss the approval of NUBEQA® (darolutamide) tablets, for oral use for metastatic hormone-sensitive prostate cancer (mHSPC).
BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
Maha Hussain
Maha Hussain is discussing the BRCAAway with Alicia Morgans, based upon Dr.